Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 4Q

Worldwide pharmaceutical sales were up 5% to $4.8 billion in the quarter.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 4Q

4Q Revenues: $8.8 billion (+11%)

4Q Earnings: $1.5 million (flat)

FY Revenues: $30.7 billion (+4%)

FY Revenues: 5.7 billion (+18%)

Comments: Worldwide pharmaceutical sales were up 5% to $4.8 billion in the quarter. International Pharmaceutical sales accounted for $2.5 billion and U.S. sales, $2.3 billion. Humira sales were $1.7 billion (+23%) and Niaspan sales were up 15% to $254 million. TriCor/Trilipix sales were $419 million (-8%). Kaletra sales were flat at $378 million. Depakote sales dropped 62% to $102 million due to generic competition. Exchange rates favorably impacted sales in the quarter by 2.5%. Nutritional sales were $1.4 billion, diagnostic sales were $975 million and vascular sales were $723 million, all up 9%. For the year, Worldwide pharmaceutical sales were $16.5 billion (-1%). International sales accounted for $8.7 billion and U.S. sales, $7.8 billion. Humira sales for the year reached $5.5 billion (+21%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters